摘要
目的了解哈尔滨市社会组织发现的男男同性性行为人群(men who have sex with men, MSM)感染人类免疫缺陷病毒(human immunodeficiency virus, HIV)的免疫状态及疾病进展,为MSM的检测策略提供依据。方法 2015年1月—2021年5月,选取哈尔滨市社会组织发现的35例MSM HIV抗体阳转患者,首次初筛阴性1例和首次免疫印迹试验(western blot, WB) HIV抗体阴性或不确定经2~8周复检阳转的34例,回顾性分析其随访检测时间、WB带型和首次CD4;T淋巴细胞及首次检测时间。结果 35例MSM中有1例首次初筛阴性和2例首次WB结果为"HIV-1抗体阴性"的阳转患者。35例MSM HIV抗体阳转患者的WB首次与复检时间间隔15~51(33.00±9.52)d。首次WB带型为gp160、p24组合23例(65.71%);首次WB带型为gp160的4例(11.43%),2例(5.71%)带型为p24。复检WB带型呈不同程度的增加,其中gp160、gp120和p24均出现;gp41占82.86%(29/35),p17占82.86%(29/35),p31占65.71%(23/35)。首次CD4;T淋巴细胞136~899(429.00±170.95)个/μl。结论不同个体间WB带型出现的时间、免疫状态和疾病进展各不相同,但大部分已进入异常的免疫状态。
Objective To discuss the characteristics of HIV testing during window period in men who have sex with men(MSM) with HIV seroconversion in Harbin, to provide reference for HIV timely diagnosis. Methods A retrospective analysis was conducted on clinical and laboratory data of 35 MSM with HIV seroconversion in Harbin from January 2015 to May 2021, including the initial screening and follow up testing, western-blot(WB) band pattern and initial CD4;T lymphocytes count. Results Among the 35 MSM with HIV seroconversion, 1 case was negative in the initial screening and 2 cases were negative in the first WB assay.The time interval between the first and second WB assay ranged from 15 to 51 days(33.00±9.52) days.In the first WB test, 23 cases(65.71%) were positive for both gp160 and p24, 3 cases(8.57%) were positive for gp160,p24 and p17, 4(11.43%) were positive for gp160 and 2(5.71%) were positive for p24.In the repeating WB test, all cases were positive for gp160, gp120 and p24, other protein bands showed up in certain cases, such as p17, gp41, p31, p51 and p55.The number of initial CD4;T lymphocyte ranged from 136 to 899/μl(429.00±170.95) μl. Conclusions The band pattern of WB test changes during the disease progression and varies among individuals.
作者
王尚博
张玲
罗超
孙烨
李春伟
沈贞姬
巩雪
梁笑天
惠洪涛
刘岩琳
WANG Shang-bo;ZHANG Ling;LUO chao;SUN Ye;LI Chun-wei;SHEN Zhen-ji;GONG Xue;LIANG Xiao-tian;HUI Hong-tao;LIU Yan-lin(Harbin Center for Disease Control and Prevention,Harbin,Heilongjiang 150056,China;不详)
出处
《中国预防医学杂志》
CAS
CSCD
北大核心
2021年第7期529-532,共4页
Chinese Preventive Medicine
基金
社会组织参与艾滋病防治基金项目(2016-2017230110PYDMSM000711-2018,2019-2020230110PYDMSM003303)。
